In addition, with an ongoing shift towards value-based payment models, there is a greater need to evaluate the impact of therapy decisions on total cost and clinical outcomes. However, we lack enough real-world evidence to start exploring these important questions.
To help solve this critical problem for myeloma, we have launched a new type of open, virtual clinical trial in partnership with COTA, a leading oncology data and technology company.
COTA has a uniquely powerful approach to transforming and stratifying real-world patient data to be able to understand the trade-offs between outcomes, quality, and cost.
This project will create a very different type of real-world patient registry:
1. There is no extra work for participants and their teams. COTA's technology extracts the data directly from your electronic medical record system via HL7 or FHIR connection; no data forms, no case report books.
2. Participants will have full access to their data via a web-based tool. In contrast to traditional "industry sponsored" registries where only a portion is shared with the executive team, you will be able to see all patients organized and fully identified, enabling easy analysis of patient volumes, treatments and outcomes. Additionally, you will be able to see all of the patients in the entire registry in a HIPAA compliant, de-identified fashion.
At this meeting you will have an opportunity to learn more about the study, see a demonstration of the COTA system, and hear an update on progress to date.
We invite you to join us during ASH on Sunday, December 4, 2016 at 6:30am at the Roy's San Diego in the Island Room for a breakfast meeting prior to the start of morning sessions.
Note: This meeting is NOT an official program of the ASH annual meeting.
Roy's San Diego
333 West Harbor Drive
COTA builds solutions for healthcare to analyze, visualize, report, and manage real-world evidence and deliver precision medicine.